PubRank

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

Clinical Trial ID NCT01656642

PubWeight™ 41.85‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01656642

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013 3.48
2 Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2013 2.64
3 Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 2015 2.25
4 Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer 2014 2.12
5 PD-1 as a potential target in cancer therapy. Cancer Med 2013 1.98
6 The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clin Ther 2015 1.73
7 Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin Oncol 2014 1.47
8 Antagonists of PD-1 and PD-L1 in Cancer Treatment. Semin Oncol 2015 1.45
9 Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. Oncotarget 2014 1.33
10 Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. Biomed Res Int 2015 1.25
11 Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014 1.24
12 Pathways and therapeutic targets in melanoma. Oncotarget 2014 1.17
13 Nivolumab in melanoma: latest evidence and clinical potential. Ther Adv Med Oncol 2015 1.09
14 BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. Onco Targets Ther 2015 0.99
15 Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014 0.98
16 Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma. Cancer Biol Med 2014 0.95
17 Checkpoint modulation in melanoma: an update on ipilimumab and future directions. Curr Oncol Rep 2013 0.94
18 Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". Toxins (Basel) 2014 0.92
19 Updates in Therapy for Advanced Melanoma. Cancers (Basel) 2016 0.91
20 Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma. Drug Des Devel Ther 2014 0.91
21 Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer. Cancer J 2014 0.88
22 Targeting the PD-1 pathway: a promising future for the treatment of melanoma. Arch Dermatol Res 2014 0.87
23 Immune checkpoint inhibitors: therapeutic advances in melanoma. Ann Transl Med 2015 0.87
24 Understanding the biology of melanoma and therapeutic implications. Hematol Oncol Clin North Am 2014 0.85
25 Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning. Oncoimmunology 2014 0.84
26 Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential. Ther Adv Med Oncol 2015 0.82
27 Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy. Semin Oncol 2015 0.82
28 PD-1 and PD-L1 antibodies for melanoma. Hum Vaccin Immunother 2014 0.80
29 Challenges and future perspectives of T cell immunotherapy in cancer. Immunol Lett 2015 0.78
30 Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2? Semin Immunol 2016 0.78
31 New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapy. Drug Healthc Patient Saf 2014 0.77
32 Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015. J Transl Med 2016 0.77
33 Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition. J Transl Med 2016 0.76
34 Targeted therapies in melanoma. Surg Oncol Clin N Am 2015 0.76
35 Innate vs. Adaptive: PD-L1-mediated immune resistance by melanoma. Oncoimmunology 2015 0.75
36 Intellectual property issues of immune checkpoint inhibitors. MAbs 2015 0.75
37 CCR 20th Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanoma-Kinase Inhibition Redux. Clin Cancer Res 2015 0.75
38 The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies. Trends Immunol 2016 0.75
Next 100